| An unusual flare of anti-synthetase syndrome during concurrent trastuzumab therapy given for recurrent breast cancer | Timothy D REYNOLDS, Vivek MOHAN, Matthew ROY, Nathan MANGHAT, Huzaifa ADAMALİ, Harsha GUNAWARDENA | 48–50 |
| Rapid loss of efficacy of biosimilar infliximab in three patients with Behçet’s disease after switching from infliximab originator | Fabrizio CANTİNİ, Laura NİCCOLİ, Carlotta NANNİNİ, Emanuele CASSARÀ, Olga KALOUDİ | 58–60 |
| Microscopic polyangiitis with dermatomyositis | Erin M BAUER, Ernest BRAHN | 61–63 |
| Cutaneous calcinosis in a patient with limited scleroderma: CREST Syndrome | Nurşen DÜZGÜN | 75–76 |
| Behçet’s disease in the United States: A single center descriptive and comparative study | Nathan C. KİLİAN, Amr H. SAWALHA | 239–244 |
| Fibromyalgia has a high prevalence and impact in cardiac failure patients | Emma K GUYMER, Andrew E AJANİ, Geoffrey O LİTTLEJOHN, Anthea C GİST | 245–249 |
| ABO blood groups and rheumatic diseases | Taşkın ŞENTÜRK, Songül ÇİLDAĞ, Yasemin KARA | 250–253 |
| The real-world use of different anti-tumor necrosis factor agents in a Northern European population of patients with Behçet’s disease | Wan Lin NG, Alexander Duncan FRASER, Joseph DEVLİN, Maria Usman KHAN, Fahd ADEEB, Austin G STACK2 | 254–263 |
| Case series: Monoarticular rheumatoid arthritis | Jeffrey SARAZİN, Rajaie N NAMAS, Elena SCHİOPU | 264–267 |
| Low frequency of HLA-B27 in ankylosing spondylitis and its relationship with clinical findings in patients from Turkey | Ayşe CEFLE, Ayten YAZICI, Hakan SAVLI, Barış YILMAZER, Sevde Nur FIRAT, Fulya COŞAN | 268–271 |
| Targeting IL-17 in psoriatic arthritis | Iannis E. ADAMOPOULOS, Emanual MAVERAKİS, Erika SUZUKİ, Elizabeth A WANG | 272–277 |
| Catastrophic antiphospholipid syndrome: A case with unusual findings revealed in autopsy and a brief literature update | Gustavo Guimarães Moreira BALBİ, Flavio SİGNORELLİ, Roger A LEVY |